EUVIMEDEUVIMED entdecken
Crossref

Prognostic Impact of Clinicopathological and Inflammatory Markers in Surgically Treated Pulmonary Invasive Mucinous Adenocarcinoma

Esra Zeynelgil, Serkan Gülcü, Dilek Çağlaya, Nesrin Gürcay, Abdulkadir Koçanoğlu, Serdar Karakaya

Seminars in Thoracic and Cardiovascular Surgery · 2026 · 38 (3) · 223-229

DOI: 10.1053/j.semtcvs.2025.08.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Seminars in Thoracic and Cardiovascular Surgery, 2026. Verfasst von Esra Zeynelgil und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ankara Atatürk Sanatoryum Training and Research Hospital, Ankara, Turkey. Electronic address: esra23.05@hotmail.com. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma, Mucinous, Pneumonectomy, Adenocarcinoma of Lung. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Invasive mucinous lung adenocarcinoma (IMA) is a rare histological subtype representing 2-10% of lung adenocarcinomas and exhibits unique molecular and clinicopathological features. Due to its rarity and the limited number of published studies, prospective studies are not possible. Therefore, prognostic markers in patients with IMA who underwent surgery are still unclear. Data from patients with histopathologically confirmed pure IMA who underwent surgery between May 2020 and December 2024 were retrospectively analyzed. Demographic data, tumor size, localization, lymph node status, visceral pleural invasion [VPI], airspace spread [STAS], adjuvant therapy, and hematological indices thought to be prognostic in other cancer types were calculated. Estimated DFS and OS were calculated by the Kaplan-Meier method, and prognostic factors were investigated by Cox regression analysis. A total of 53 patients with surgically resected mucinous adenocarcinoma were included in the study. The median age was 66 years (range: 36-88). Of the patients, 54.7% were male (n = 29) and 45.3% were female (n = 24). Nineteen patients (35.8%) received adjuvant chemotherapy, and 7 patients (13.2%) received adjuvant radiotherapy. Postoperative pathological examination revealed that 24 patients (45.3%) had tumors ≥4 cm in diameter, 6 patients (11.3%) had lymph node metastasis, and 10 patients (18.9%) were STAS-positive. The estimated median disease-free survival (mDFS) for the overall population was 98.9 months. In patients with lymph node metastasis, mDFS was 4.5 months, while the median was not reached in patients without nodal involvement (log-rank, p < 0.001). In the presence of pleural invasion, mDFS was 42.7 months, while it was not reached in patients without invasion (log-rank, p = 0.008). In STAS-positive patients, mDFS was 18.6 months, compared to not reached in STAS-negative patients (log-rank, p = 0.039). For tumors ≥4 cm, mDFS was 47.1 months, while it was not reached for tumors

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinoma, MucinousPneumonectomyAdenocarcinoma of LungInflammation MediatorsHumansFemaleMaleMiddle AgedAgedRetrospective StudiesAdultAged, 80 and overNeoplasm InvasivenessTime FactorsRisk FactorsTreatment OutcomeBiomarkers, TumorRisk AssessmentLymphatic MetastasisChemotherapy, Adjuvant

Stichwörter der Autor:innen

Inflammatory markersInvasive mucinous adenocarcinoma cancerPrognostic factorsSurgery

Substanzen

Biomarkers, TumorInflammation Mediators

Autor:innen und Institutionen

  • Department of Medical Oncology, Ankara Atatürk Sanatoryum Training and Research Hospital, Ankara, Turkey. Electronic address: esra23.05@hotmail.com.
  • Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey.
  • Department of Medical Oncology, Nevşehir State Hospital, Nevşehir, Turkey.
  • Department of Pathology, Ankara Atatürk Sanatoryum Training and Research Hospital, Ankara, Turkey.
  • Department of Medical Oncology, Ankara Atatürk Sanatoryum Training and Research Hospital, Ankara, Turkey.

Zitieren

APA

Zeynelgil, E., Gülcü, S., Çağlaya, D., Gürcay, N., Koçanoğlu, A., & Karakaya, S. (2026). Prognostic Impact of Clinicopathological and Inflammatory Markers in Surgically Treated Pulmonary Invasive Mucinous Adenocarcinoma. Seminars in Thoracic and Cardiovascular Surgery, 38(3), 223-229. https://doi.org/10.1053/j.semtcvs.2025.08.007

Vancouver

Zeynelgil E, Gülcü S, Çağlaya D, Gürcay N, Koçanoğlu A, Karakaya S. Prognostic Impact of Clinicopathological and Inflammatory Markers in Surgically Treated Pulmonary Invasive Mucinous Adenocarcinoma. Seminars in Thoracic and Cardiovascular Surgery. 2026;38(3):223-229. doi:10.1053/j.semtcvs.2025.08.007

BibTeX
@article{Zeynelgil2026,
  author = {Zeynelgil, Esra and Gülcü, Serkan and Çağlaya, Dilek and Gürcay, Nesrin and Koçanoğlu, Abdulkadir and Karakaya, Serdar},
  title = {Prognostic Impact of Clinicopathological and Inflammatory Markers in Surgically Treated Pulmonary Invasive Mucinous Adenocarcinoma},
  journal = {Seminars in Thoracic and Cardiovascular Surgery},
  year = {2026},
  volume = {38},
  number = {3},
  pages = {223--229},
  doi = {10.1053/j.semtcvs.2025.08.007}
}
Kostenlos starten →